Iraqi Postgraduate Medical Journal

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

Copyrights and Licensing

Home

About Journal

Aim and Scope

Editorial Board

Peer Review Process

Copyrights and Licensing

Indexing and Abstracting

Plagiarism Policy

Author's Guide

Article processing charge (APC)

Clinicopathological spectrum of IgA Nephropathy in Ebil teaching hospital, A retrospective single center study

,

Document Type : Research Paper

Abstract

Abstract:
Background:
The leading cause of glomerulonephritis that occurs most frequently and has the greatest morbidity and mortality rates worldwide are Immunoglobulin A nephropathy (IgAN). Internationally, the prevalence and clinicopathological range of primary Immunoglobin A nephropathy (IgAN) is diverse. This study aims to assess the clinical, pathological, and laboratory characteristics of male and female IgANpatients.
Methods:
This is a retrospective Single center study, conducted in Erbil teaching hospital. All Native biopsy reports from 2015 to 2021 were reviewed and those with the diagnosis of IgA nephropathy were selected and their pathological, clinical, and laboratory data were analyzed and categorized using the Oxford categorization method.
Results:
Out of 2649 biopsies done from 2015 to 2021 167. had IgA nephropathy, hence prevalence is
6.3%. Mean age was 34.03, Males comprised (67.1%), Females (32.9%). (68.3%) of patients had hypertension, (49.7%) of the patients had renal impairment, 38% had microscopic hematuria, and 19.8% had macroscopic haematuria. More than half (56.3%) of the males had renal impairment, compared with 36.4% of females (p = 0.016)
Conclusion
Ig A nephropathy is common with variable presentations. Males have worse clinical and pathological features. High BMI is associated with higher blood pressure and more proteinuria. Larger studies are required to confirm, these findings.

Keywords

Main Subjects

References
  1. Donadio J, Grande J. IgA Nephropathy. New England Journal of Medicine. 2002;347:738-48.
  2. Berger J, Hinglais N. Les ddpôts intercapillaires d'IgA-IgG [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris). 1968;74:694-95. French. PMID: 4180586
  3. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987;64:709-27.
  4. Seedat Y, Nathoo B, Parag K, Naiker I, Ramsaroop R. IgA Nephropathy in Blacks and Indians of Natal. Nephron. 1988;50:137-41.
  5. Levy M, Berger J. Worldwide Perspective of IgA Nephropathy. American Journal of Kidney Diseases. 1988;12:340-47.
  6. Magistroni R, D’Agati V, Appel G, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney International. 2015;88:974-89.
  7. Wyatt R, Julian B. IgA Nephropathy. New England Journal of Medicine. 2013;368:2402-14. Barbour S, Coppo R, Zhang H, Liu Z, Suzuki Y, Matsuzaki K et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Internal Medicine. 2019;179:942.
  8. Roberts I, Cook H, Troyanov S, Alpers C, Amore A, Barratt J et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney International. 2009;76:546-56.
  9. Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford classification of IGA nephropathy 2016: An update from the IGA Nephropathy Classification Working Group. Kidney International. 2017;91:1014–21.
  10. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59. Kidney International Supplements. 2017;7:e1.
  11. Barbour S, Coppo R, Zhang H, Liu Z, Suzuki Y, Matsuzaki K et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Internal Medicine. 2019;179:942.
  12. Rodrigues J, Haas M, Reich H. IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 2017;12:677-86.
  13. Ghani A, Al Waheeb S, Al Homoud E, Al Helal B, Hussain N. Clinical and histopathological spectrum of IgA nephropathy in Kuwait. Annals of Saudi Medicine. 2011;31:152-57.
  14. Siddappa S, Mythri K, Kowsalya R. IgA nephropathy in a tertiary care center from south India. Indian Journal of Nephrology. 2011;21:230.
  15. Chandrika B. IgA nephropathy in Kerala, India: A retrospective study. Indian Journal of Pathology and Microbiology. 2009;52:14.
  16. Bhat M, Sofi I, Sheikh R, Wani I. Incidence, demographic, biochemical, and clinicopathological profile of primary IgAN in a tertiary care center from Northern India. The Egyptian Journal of Internal Medicine. 2022;34.
  17. Storrar J, Chinnadurai R, Sinha S, Kalra P. The epidemiology and evolution of IgA nephropathy over two decades: A single centre experience. PLOS ONE. 2022;17:e0268421.
  18. . Coppo R, Troyanov S, Bellur S, Cattran D, Cook H, Feehally J et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney International. 2014;86:828-36.
  19. Alexander S, Varughese S, Franklin R, Roy S, Rebekah G, David V et al. Epidemiology, baseline characteristics and risk of progression in the first South-Asian prospective longitudinal observational IgA nephropathy cohort. Kidney International Reports. 2021;6:414-28.
  20. Li P, Ho K, Szeto C, Yu L, Lai F. Prognostic indicators of IgA nephropathy in the Chinese-clinical and pathological perspectives. Nephrology Dialysis Transplantation. 2002;17:64-69.
  21. Chowdry A, Najar M, Mir M, Azad H, Rashid R, Ashraf B et al. Primary IgA nephropathy in the Kashmiri population. Saudi Journal of Kidney Diseases and Transplantation. 2018;29:680.
  22. Lai K, Lai F, Li P, Chan K, Au T, Tong K. The clinicopathological characteristics of IgA nephropathy in Hong Kong. Pathology. 1988;20:15-19.
  23. Riispere Ž, Laurinavičius A, Kuudeberg A, Seppet E, Sepp K, Ilmoja M et al. IgA nephropathy clinicopathologic study following the Oxford classification: Progression peculiarities and gender-related differences. 2022.
  24. Jha V, Mahapatra D, Jairam A. Clinical Profile, Histopathological Features and Outcome of IgA Nephropathy in a Tertiary Care Hospital in India. Saudi Journal of Kidney Diseases and Transplantation. 2020;31:1091.
  25. Deng W, Tan X, Zhou Q, Ai Z, Liu W, Chen W et al. Gender-related differences in clinicopathological characteristics and renal outcomes of Chinese patients with IgA nephropathy. BMC Nephrology. 2018;19.
  26. Wen D, Tang Y, Tan L, Tan J, Chen D, Zhang Y et al. Sex disparities in IgA nephropathy: a retrospective study in Chinese patients. International Urology and Nephrology. 2020;53:315-23.
  27. Schimpf J, Klein T, Fitzner C, Eitner F, Porubsky S, Hilgers R et al. Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores). BMC Nephrology. 2018;19.
  28. Kang S, Choi S, Park H, Lee J, Sun I, Hwang H et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrology Dialysis Transplantation. 2011;27:252-58.
  29. Lv J, Shi S, Xu D, Zhang H, Troyanov S, Cattran D et al. Evaluation of the Oxford Classification of IgA Nephropathy: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases. 2013;62:891-99.
  • Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C. The Use of the Oxford Classification of IgA Nephropathy to Predict Renal Survival. Clinical Journal of the American Society of Nephrology. 2011;6:2384-88.
  • Herzenberg A, Fogo A, Reich H, Troyanov S, Bavbek N, Massat A et al. Validation of the Oxford classification of IgA nephropathy. Kidney International. 2011;80:310-17.
  1. Deng W, Tan X, Zhou Q, Ai Z, Liu W, Chen W et al. Gender-related differences in clinicopathological characteristics and renal outcomes of Chinese patients with IgA nephropathy. BMC Nephrology. 2018;19.
  • Bobart SA, Alexander MP, Shawwa K, Vaughan LE, Ghamrawi R, Sethi S, et al. The Association of Microhematuria with mesangial hypercellularity, endocapillary hypercellularity, Crescent score and renal outcomes in immunoglobulin a nephropathy. Nephrology Dialysis Transplantation. 2019;36:840–47.
  • Gowrishankar S, Gupta Y, Vankalakunti M, Gowda K, Kurien A, Jansi Prema K et al. Correlation of Oxford MEST-C Scores With Clinical Variables for IgA Nephropathy in South India. Kidney International Reports. 2019;4:1485-90.
  • Wen D, Tang Y, Tan L, Tan J, Chen D, Zhang Y et al. Sex disparities in IgA nephropathy: a retrospective study in Chinese patients. International Urology and Nephrology. 2020;53:315-23.
  • Deng W, Tan X, Zhou Q, Ai Z, Liu W, Chen W et al. Gender-related differences in clinicopathological characteristics and renal outcomes of Chinese patients with IgA nephropathy. BMC Nephrology. 2018;19.
  • Wang Q, Zhang J, Dou W, Zeng H, Shi P, Wu J. Impact of body mass index on primary immunoglobulin A nephropathy prognosis: a systematic review and meta-analysis. International Urology and Nephrology. 2021;54:1067-78.

 Berthoux F, Mariat C, Maillard N. Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy. Nephrology Dialysis Transplantation. 2013;28:iv160-iv166.

  1. Hong Y, Min J, Ha M, Koh E, Kim H, Ban T et al. The Impact of Obesity on the Severity of Clinicopathologic Parameters in Patients with IgA Nephropathy. 2022.
  2. Wu C, Wang A, Li G, Wang L. Association of high body mass index with development of interstitial fibrosis in patients with IgA nephropathy. BMC Nephrology. 2018;19.

 

 

Iraqi Postgraduate Medical Journal
Volume 23, Issue 2
April 2024
Page 211-221
Files
Share
Export Citation
Statistics